Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

873
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
873
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

765
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
765
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>RAI1</i> safeguards fidelity and tempo of human neurodevelopmental gene expression.

bioRxiv : the preprint server for biology·2026
Same author

Dual endomembrane recycling pathways function in parallel to support synapse maintenance and plasticity.

Neuroscience·2025
Same author

PI(3)P coordinates SNX17- and SNX27-dependent protein recycling for long-term synaptic plasticity.

The Journal of cell biology·2025
Same author

Division of labor among H3K4 methyltransferases defines distinct facets of homeostatic plasticity.

Cell reports·2025
Same author

Division of labor among H3K4 Methyltransferases Defines Distinct Facets of Homeostatic Plasticity.

bioRxiv : the preprint server for biology·2023
Same author

Recruitment of the SNX17-Retriever recycling pathway regulates synaptic function and plasticity.

The Journal of cell biology·2023

Related Experiment Video

Updated: Mar 6, 2026

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

11.8K

Vesicular Glutamate Transporter Inhibitors: Structurally Modified Brilliant Yellow Analogs.

Jason Kehrl1,2, J Christian Althaus1, Hollis D Showalter3,4

  • 1Molecular & Behavioral Neuroscience Institute, Medical School, University of Michigan, 109 Zina Pitcher, Ann Arbor, MI, 48109, USA.

Neurochemical Research
|March 4, 2017
PubMed
Summary

Researchers developed novel, non-toxic Brilliant Yellow analogs that selectively inhibit vesicular glutamate transporters (VGLUTs). These membrane-permeable agents offer a new tool for studying glutamate neurotransmission and related neurological disorders.

Keywords:
Brilliant YellowCytotoxicityStructural modificationVGLUT-selective inhibitionVesicular glutamate uptake

More Related Videos

Deriving the Time Course of Glutamate Clearance with a Deconvolution Analysis of Astrocytic Transporter Currents
09:42

Deriving the Time Course of Glutamate Clearance with a Deconvolution Analysis of Astrocytic Transporter Currents

Published on: August 7, 2013

10.9K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

11.8K
Deriving the Time Course of Glutamate Clearance with a Deconvolution Analysis of Astrocytic Transporter Currents
09:42

Deriving the Time Course of Glutamate Clearance with a Deconvolution Analysis of Astrocytic Transporter Currents

Published on: August 7, 2013

10.9K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.7K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Vesicular glutamate transporters (VGLUTs) are crucial for glutamate synaptic transmission, regulating the excitatory neurotransmitter.
  • VGLUTs are implicated in numerous nervous system functions and pathological conditions.
  • Existing VGLUT inhibitors are membrane-impermeable and potentially cytotoxic due to diazo and sulfonic acid groups.

Purpose of the Study:

  • To develop novel VGLUT-specific agents with improved properties for studying neuronal function.
  • To create membrane-permeable and non-cytotoxic VGLUT inhibitors.

Main Methods:

  • Synthesis of novel Brilliant Yellow analogs (1 and 2) lacking diazo and sulfonic acid groups.
  • Assessment of VGLUT-selective inhibitory activity.
  • Evaluation of cellular toxicity in intact neurons.

Main Results:

  • The novel Brilliant Yellow analogs demonstrated highly VGLUT-selective inhibitory activity.
  • These agents exhibited no significant cellular toxicity.
  • The modified compounds are membrane-permeable, unlike previous inhibitors.

Conclusions:

  • Novel Brilliant Yellow analogs represent a significant advancement in developing tools for VGLUT research.
  • These non-toxic, membrane-permeable inhibitors offer potential for investigating VGLUT function in intact neuronal systems.
  • This molecular modification strategy could be valuable for developing new therapeutic agents targeting VGLUTs.